BridgeBio Pharma's Encaleret Shows Positive Phase 2 Results, Normalizes Calcium in Post-Surgical Hypoparathyroidism

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the most promising long-term stocks to buy. On September 6, BridgeBio Pharma announced that its investigational, orally-administered therapy, called encaleret, demonstrated parathyroid hormone/PTH-independent normalization of blood and urine calcium in patients with post-surgical hypoparathyroidism.

These positive findings from a Phase 2 proof-of-concept study were presented in an oral presentation at the American Society for Bone and Mineral Research/ASBMR Annual Meeting 2025. The Phase 2 study was designed to evaluate the PTH-independent effects of encaleret on renal calcium handling in 10 participants with post-surgical hypoparathyroidism.

Participants were administered encaleret at 162 mg twice daily for up to 5 days. Calcitriol, which is a conventional therapy component, was stopped one day before the first dose of encaleret. Key results showed that encaleret treatment led to a rapid and sustained reduction in fractional excretion of calcium in 9 participants

BridgeBio Pharma Inc. (NASDAQ:BBIO) is a commercial-stage biopharmaceutical company that discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.